Filter

571 - 580 of 800 Results

  • Medicaid and the Prescription Drug Benefit

    Issue Brief

    This policy brief includes background information on Medicaid and its drug benefit, provides examples of how states are using the cost containment mechanisms at their disposal and addresses issues surrounding beneficiary access to outpatient drugs. Policy Brief

  • Demand Effects of Recent Changes in Prescription Drug Promotion

    Report

    The rapid increase in DTC advertising for prescription drugs has focused attention on its role in drug spending and prescribing. A new study by researchers at Harvard University and the Massachusetts Institute of Technology looks at the effect of direct-to-consumer (DTC) advertising on spending for prescription drugs. The study found that, on average, a 10% increase in DTC advertising of drugs within a therapeutic drug class resulted in a 1% increase in sales of the…

  • President Bush’s Budget:  An Overview of Health Programs

    Other Post

    President Bush's Budget: An Overview of Health Programs A new Foundation presentation provides an overview of President Bush s federal budget proposal for Fiscal Year 2002, focusing on its impact on health programs. The budget largely keeps pace with expected growth in Medicare and Medicaid, creates a prescription drug block grant to states for low-income seniors, proposes decreased funding for some public health programs, and would provide either limited or no growth for central programs…

  • Prescription Drug Coverage for Medicare Beneficiaries

    Other Post

    A Side-by-Side Comparison of Selected Proposals as of February 15, 2000 This document provides a side-by-side comparison of five major federal proposals that have been considered to provide outpatient prescription drug coverage to Medicare beneficiaries. It begins with a summary table comparing key features of each proposal, followed by a detailed comparison of the following major proposals: Breaux/Frist, Clinton, Kennedy/Stark, Snowe/Pallone, and Bilirakis/Peterson. For more background on the issue of prescription drugs for Medicare beneficiaries,…

  • Health News Index – September/October 2000

    Poll Finding

    Health News Index September/October, 2000 The September/October 2000 edition of the Kaiser Family Foundation/HarvardSchool of Public Health, Health News Index includes questions about how closely the public is following and how well they understand major health stories covered in the news during September, including stories about presidential candidates Al Gore and George W. Bush's prescription drug proposals. Every two months, Kaiser/Harvard issues a new index report. HNI September-October 2000 Topline/Survey MEDIA ADVISORY Download

  • Medicaid and Prescription Drugs

    Fact Sheet

    An updated fact sheet summarizing the latest statistics and trends regarding the role of Medicaid in providing prescription drug coverage. Fact Sheet

  • Medicare Prescription Drug Plans in 2009 and Key Changes Since 2006: Summary of Findings

    Issue Brief

    Since 2006, Medicare beneficiaries have had access to prescription drug coverage offered by private plans, either stand-alone prescription drug plans (PDPs) or Medicare Advantage prescription drug plans (MA-PD plans). Today, more than 26 million Medicare beneficiaries are enrolled in Medicare drug plans, including 17.5 million in stand-alone prescription drug plans and 9 million in Medicare Advantage drug plans. This report summarizes findings from a series of Medicare Part D 2009 Data Spotlights documenting changes in…

  • Health Care Costs Survey – Toplines

    Poll Finding

    This document includes the toplines from the joint USA Today/Kaiser/Harvard School of Public Health survey exploring Americans’ views on health care costs. Survey Toplines (.pdf)

  • Report Examines Trends in the Medicare Part D Plan Marketplace

    News Release

    A new comprehensive Kaiser Family Foundation report analyzes key trends that have shaped the Medicare Part D marketplace since the program launched nine years ago, providing a detailed assessment of changes in plan availability, enrollment, premiums and cost sharing in both private stand-alone drug plans, and Medicare Advantage drug plans.